Journal article
Weaponizing natural killer cells for solid cancer immunotherapy
JKM Wong, R Dolcetti, H Rhee, F Simpson, F Souza-Fonseca-Guimaraes
Trends in Cancer | CELL PRESS | Published : 2023
Abstract
Enhancing natural killer (NK) cell-based innate immunity has become a promising strategy for immunotherapy against hard-to-cure solid cancers. Monoclonal antibody (mAb) therapy has been used to activate NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) towards solid cancers. Cancer cells, however, can subvert immunosurveillance using multiple immunosuppressive mechanisms, which may hamper NK cell ADCC. Mechanisms to safely enhance ADCC by NK cells, such as utilizing temporary inhibition of receptor endocytosis to increase antibody presentation from target to effector cells can now be used to enhance NK-cell-mediated ADCC against solid tumors. This review summarizes and discuss..
View full abstractRelated Projects (1)
Grants
Awarded by U.S. Department of Defense
Funding Acknowledgements
& nbsp;The authors thank Timothy McCulloch, Natacha Omer, Ilan Gobius and Gustavo Rodrigues Rossi for critical comments and editing support. J.K.M.W. is supported by a University of Queensland PhD scholarship F.S-F-G. is funded by a UQ Diamantina Institute Laboratory Start-Up Package, a US Department of Defense - Breast Cancer Research Program - Breakthrough Award Level 1 (#BC200025) , and a ANZSA Sarcoma Research Grant (supported by Kicking Goals for Xav, Stoney 's Steps and Stop Sarcoma) . R.D. is supported by a National Breast Cancer Foundation (IIRS-18-047) . F.S. is supported by a NHMRC Ideas grant (GNT2001396) .